These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

228 related items for PubMed ID: 18249537

  • 1. Development of pyridopyrimidines as potent Akt1/2 inhibitors.
    Wu Z, Hartnett JC, Neilson LA, Robinson RG, Fu S, Barnett SF, Defeo-Jones D, Jones RE, Kral AM, Huber HE, Hartman GD, Bilodeau MT.
    Bioorg Med Chem Lett; 2008 Feb 15; 18(4):1274-9. PubMed ID: 18249537
    [Abstract] [Full Text] [Related]

  • 2. Rapid assembly of diverse and potent allosteric Akt inhibitors.
    Wu Z, Robinson RG, Fu S, Barnett SF, Defeo-Jones D, Jones RE, Kral AM, Huber HE, Kohl NE, Hartman GD, Bilodeau MT.
    Bioorg Med Chem Lett; 2008 Mar 15; 18(6):2211-4. PubMed ID: 18296048
    [Abstract] [Full Text] [Related]

  • 3. Optimization of 2,3,5-trisubstituted pyridine derivatives as potent allosteric Akt1 and Akt2 inhibitors.
    Hartnett JC, Barnett SF, Bilodeau MT, Defeo-Jones D, Hartman GD, Huber HE, Jones RE, Kral AM, Robinson RG, Wu Z.
    Bioorg Med Chem Lett; 2008 Mar 15; 18(6):2194-7. PubMed ID: 18294842
    [Abstract] [Full Text] [Related]

  • 4. Discovery of pyrrolopyrimidine inhibitors of Akt.
    Blake JF, Kallan NC, Xiao D, Xu R, Bencsik JR, Skelton NJ, Spencer KL, Mitchell IS, Woessner RD, Gloor SL, Risom T, Gross SD, Martinson M, Morales TH, Vigers GP, Brandhuber BJ.
    Bioorg Med Chem Lett; 2010 Oct 01; 20(19):5607-12. PubMed ID: 20810279
    [Abstract] [Full Text] [Related]

  • 5. Triazolo[1,5-a]pyrimidines as novel CDK2 inhibitors: protein structure-guided design and SAR.
    Richardson CM, Williamson DS, Parratt MJ, Borgognoni J, Cansfield AD, Dokurno P, Francis GL, Howes R, Moore JD, Murray JB, Robertson A, Surgenor AE, Torrance CJ.
    Bioorg Med Chem Lett; 2006 Mar 01; 16(5):1353-7. PubMed ID: 16325401
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Discovery of dihydrothieno- and dihydrofuropyrimidines as potent pan Akt inhibitors.
    Bencsik JR, Xiao D, Blake JF, Kallan NC, Mitchell IS, Spencer KL, Xu R, Gloor SL, Martinson M, Risom T, Woessner RD, Dizon F, Wu WI, Vigers GP, Brandhuber BJ, Skelton NJ, Prior WW, Murray LJ.
    Bioorg Med Chem Lett; 2010 Dec 01; 20(23):7037-41. PubMed ID: 20971641
    [Abstract] [Full Text] [Related]

  • 11. Synthesis of 2-amino-4-(7-azaindol-3-yl)pyrimidines as cyclin dependent kinase 1 (CDK1) inhibitors.
    Huang S, Li R, Connolly PJ, Emanuel S, Middleton SA.
    Bioorg Med Chem Lett; 2006 Sep 15; 16(18):4818-21. PubMed ID: 16870444
    [Abstract] [Full Text] [Related]

  • 12. Discovery of 4-amino-N-[(1S)-1-(4-chlorophenyl)-3-hydroxypropyl]-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamide (AZD5363), an orally bioavailable, potent inhibitor of Akt kinases.
    Addie M, Ballard P, Buttar D, Crafter C, Currie G, Davies BR, Debreczeni J, Dry H, Dudley P, Greenwood R, Johnson PD, Kettle JG, Lane C, Lamont G, Leach A, Luke RW, Morris J, Ogilvie D, Page K, Pass M, Pearson S, Ruston L.
    J Med Chem; 2013 Mar 14; 56(5):2059-73. PubMed ID: 23394218
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Synthesis and biological evaluation of imidazo[4,5-b]pyridine and 4-heteroaryl-pyrimidine derivatives as anti-cancer agents.
    Lukasik PM, Elabar S, Lam F, Shao H, Liu X, Abbas AY, Wang S.
    Eur J Med Chem; 2012 Nov 14; 57():311-22. PubMed ID: 23085105
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Macrocyclic aminopyrimidines as multitarget CDK and VEGF-R inhibitors with potent antiproliferative activities.
    Lücking U, Siemeister G, Schäfer M, Briem H, Krüger M, Lienau P, Jautelat R.
    ChemMedChem; 2007 Jan 14; 2(1):63-77. PubMed ID: 17131463
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.